Most organisations don’t fail because of science — they fail because value leaks quietly across decisions that feel rational in isolation.
I help CEOs, COOs, and strategic leaders in biotech, medtech, CDMO, and university spin-outs identify where this hidden leakage is eroding runway, valuation, and deal outcomes before it shows up in their financials or investor conversations.
The challenge I solve is not about cost cutting, tools, or headcount — it’s about seeing what escapes standard operational and financial reviews:
• strategic misalignment between R&D and commercial value
• costly downstream consequences of early technical decisions
• regulatory and manufacturing risks that quietly inflate cost exposure
• organisational design that optimises functions, but not enterprise value
If you’re wrestling with uncertainty around cost, value, or strategic risk — and want clarity before it becomes a constraint on growth or deals — I’m open to a private conversation to explore where hidden leakage resides in your organisation.
Visit the Life Science Cost Leakage Audit™ page for further details on this diagnostic approach.